CYANIMAL

In addition to their crucial epidemiological role, vaccines for the pet market are key products for the entire chain whether for the loaboratories or for the veterinarians themselves.

To date, most of the vaccines dedicated to pets are attenuated or inactivated vaccines. In some cases, the safety or the efficiency is not fully reached. Consequently, veterinaries have to deal with the balance efficiency/side effect risks and have to adapt their vaccination protocol according to the animal health association recommendations.

Cyanimal has developed an unique, efficient and proprietary antigen delivery platform with a better safety balance, which is used to increase the efficiency of already commercialised vaccines or to develop new prophylactic and therapeutic vaccines for unmet needs. The technology strengths are based on the CyaA recombinant bacterial vector which is (i) safe and secure (non-replicative), (ii) specific to Antigen Presenting Cells APCs (immune response oriented), (iii) easy to produce and stable (iv) very well tolerated and (v) can be used in a prophylactic or therapeutic vaccine.

Proof of concept has been obtained in a clinical trial for the first vaccine candidate developed in the indication of the canine infection respiratory disease (CIRD).  Very strong and specific cellular and humoral responses (Th1 type immune response) have been observed. In addition, clinical protection along a three months experiment on 15 puppies is very concluding.